Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Q32 Bio Inc. is a biotechnology company developing antibody-based therapeutics targeting immune pathways involved in autoimmune and inflammatory diseases. Its pipeline includes bempikibart, an IL-7Rα antagonist for alopecia areata and atopic dermatitis, and ADX-097, a tissue-targeted complement inhibitor for autoimmune conditions. The company focuses on innovative biologics, leveraging proprietary patents, strategic collaborations, and a clinical-stage model to address unmet medical needs in immune dysregulation.
This description was generated via AI from an annual report. Updated about 1 year ago.